posted stronger-than-expected third quarter earnings Tuesday, while boosting its full-year profit forecast, thanks in part to solid gains for its new cancer treatments.
Pharmaceuticals sales were up 5.1% to $13.9 billion while Medtech sales jumped 10% to $7.46 billion. Consumer health sales were spun-off to Kenvue, the group's stand-alone entity, earlier this year.
این خبر را خلاصه کرده ایم تا بتوانید سریع آن را بخوانید. اگر به خبر علاقه مند هستید، می توانید متن کامل را اینجا بخوانید. ادامه مطلب:
ایران آخرین اخبار, ایران سرفصلها
Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.
Johnson & Johnson Reports Earnings Tuesday. What to ExpectAn update in August after the split leaves investors with fewer questions for Tuesday's results.
منبع: MarketWatch - 🏆 3. / 97 ادامه مطلب »
Johnson & Johnson earnings: What to expectJohnson & Johnson is not expected to produce big surprises in its earnings release due Tuesday
منبع: MarketWatch - 🏆 3. / 97 ادامه مطلب »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
منبع: NBCLA - 🏆 319. / 59 ادامه مطلب »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
منبع: NBCNewYork - 🏆 270. / 63 ادامه مطلب »
Johnson & Johnson's stock climbs after company beats earnings estimates and raises profit guidanceJohnson & Johnson raised its full year EPS guidance and lifted the midpoint of its sales range
منبع: MarketWatch - 🏆 3. / 97 ادامه مطلب »